LRRN4CL Inhibitors
LRRN4CL inhibitors encompass a diverse set of compounds that act upon various signaling pathways and cellular processes to indirectly diminish the activity of LRRN4CL.Compounds like LY294002, Wortmannin, U0126, PD98059, and Gö 6983 inhibit specific kinases (e.g., PI3K, MEK, PKC) that are part of signaling cascades. If LRRN4CL is regulated by these pathways, these inhibitors will indirectly reduce its activity.SB203580 and SP600125, which target p38 MAPK and JNK respectively, will downregulate LRRN4CL if it is involved in cellular responses to stress mediated by these kinases.Rapamycin's inhibition of mTOR could decrease LRRN4CL activity if mTOR pathway is involved in its regulation, as mTOR influences many cellular processes including growth and metabolism.
PP2 affects Src family kinases. If Src kinases are involved in signaling pathways that regulate LRRN4CL, PP2 would indirectly reduce its activity.Y-27632 and Blebbistatin inhibit ROCK and myosin II, respectively, which play roles in the organization of the actin cytoskeleton and cell motility. If LRRN4CL is related to these processes, its activity would be impacted.ML-7 inhibits myosin light chain kinase, which might affect LRRN4CL activity if it's associated with MLCK-regulated processes.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a potent inhibitor of phosphoinositide 3-kinases (PI3K). By blocking the ATP-binding site of PI3K, LY294002 effectively decreases PI3K/AKT pathway activity. If LRRN4CL is associated with this signaling pathway, LY294002 would result in diminished phosphorylation of AKT, thereby inhibiting any LRRN4CL activity that is modulated through this pathway. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is a selective inhibitor of MEK1/2, the upstream kinase for ERK1/2 in the MAPK pathway. By inhibiting MEK1/2, U0126 prevents the activation of ERK1/2, which may be critical for certain transcriptional events. If LRRN4CL activity is dependent on transcription factors activated by ERK, the inhibition of MEK1/2 would result in a decrease in LRRN4CL activity. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is a non-competitive inhibitor of MEK1/2. It specifically blocks the activation of MEK1/2, thereby inhibiting the downstream activation of ERK1/2. Inhibition of this pathway would lead to reduced activity of LRRN4CL if it is regulated by signals transmitted through ERK1/2. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a selective inhibitor of p38 MAPK. By inhibiting p38 MAPK, SB203580 disrupts the cellular response to stress and cytokines. If LRRN4CL is influenced by stress signals that involve p38 MAPK, then its activity would be inhibited as a result of SB203580's action. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 selectively inhibits JNK, which is involved in controlling gene expression in response to stress. If LRRN4CL activity is modulated by JNK, then its inhibition by SP600125 would lead to decreased LRRN4CL activity. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is an inhibitor of PI3K, resulting in the inhibition of AKT phosphorylation. By impeding PI3K/AKT signaling, wortmannin indirectly leads to decreased activity of LRRN4CL if it is part of this signaling pathway. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin inhibits mTORC1 by binding to FKBP12. This complex then inhibits mTOR activity, which is crucial for protein synthesis and cell growth. If LRRN4CL's function is under the control of mTOR signaling, then rapamycin would indirectly decrease LRRN4CL activity. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $92.00 $223.00 | 30 | |
PP2 is an Src kinase inhibitor. Src kinases are involved in various signaling pathways that regulate cellular processes. If LRRN4CL is regulated by Src kinase signaling, PP2 would indirectly inhibit LRRN4CL activity. | ||||||
Gö 6983 | 133053-19-7 | sc-203432 sc-203432A sc-203432B | 1 mg 5 mg 10 mg | $103.00 $293.00 $465.00 | 15 | |
Gö 6983 inhibits PKC isoforms. Since PKC is involved in the regulation of numerous cellular functions, inhibition by Gö 6983 could lead to reduced LRRN4CL activity if LRRN4CL is a downstream effector of PKC. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $182.00 $693.00 | 88 | |
Y-27632 is a ROCK inhibitor. ROCK is involved in actin cytoskeleton organization affecting cell shape and motility. If LRRN4CL is related to these processes, inhibition by Y-27632 would lead to decreased LRRN4CL activity. | ||||||